[328 Pages Report] The global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market was valued at US$ 3.8 Bn in 2021 and is expected to reach US$ 5.5 Bn by 2030, finds Future Market Insights (FMI) in a recent market survey.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 3.9 Billion |
| Market Value 2030 | USD 5.5 Billion |
| CAGR 2022 to 2030 | 4.3% |
| Key Players | The key players are Pfizer, Inc., Allergan Plc., Johnsons & Johnson, Colgate-Palmolive Company, The Procter & Gamble, Merck & Co., Inc., Baxter Healthcare Corporation, Fresenius Kabi LLC, Sandoz Inc., Teva Pharmaceutical Industries ltd., Mylan N. V., Dr.Reddy's Laboratories Inc., Cumberland Pharmaceuticals Inc., Durata Therapeutics Inc., Melinta Therapeutics, Inc., Debiopharm International S.A., Cardinal Health, Amazon Inc., Herbal Intervention, LLC, 3M ESPE Dental Products, Patterson Dental Supply Inc., The Kroger Company, Crown Laboratories, Inc., Atlantic Biologicals Corp., Bio-Germ Protection LLC and Apollo Health and Beauty Care |
| Share of Top 5 Countries | 65.9% |
The methicillin-resistant staphylococcus aureus (MRSA) treatment market is anticipated to witness robust growth due to the growing incidence rate of MRSA infections, increasing number of pipeline products, and growing product approval & launches for the MRSA infection treatment.
One of the significant type of MRSA infection is surgical infections. This risk of infections is associated with several surgical conditions which demand surgical procedures. Rising number of surgical conditions from chronic diseases such as diabetes, chronic respiratory and renal diseases are expected to increase the demand of post-operative MRSA anti-infective therapies.
Methicillin-resistant staphylococcus aureus (MRSA) treatment market holds nearly 18.1% market value share of the US$ 21 Bn skin disease treatment market in 2021. In addition, leading industry players are focusing on development and launch of next generation antibiotics to treat MRSA infections. This accelerated availability of antibiotics in the market is expected to boost the MRSA treatment market.
Driven by this, sales of methicillin-resistant staphylococcus aureus (MRSA) treatment are expected to rise at a 4.3% CAGR through 2030.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 4.25% |
| H1, 2022 Projected | 4.34% |
| H1, 2022 Outlook | 4.24% |
| BPS Change - H1, 2022 (O) – H1, 2022 (P) | (-) 10 ↓ |
| BPS Change – H1, 2022 (O) – H1, 2021 | (-) 1 ↓ |
FMI presents a comparative analysis about the market growth rates and development prospects in the global methicillin resistant Staphylococcus aureus (MRSA) treatment market. In response to the impact of macro and industrial factors, the market is influenced by an increase in patient base and economic disparities in regional medical setups. Source control and the initiation of active antimicrobial therapy are two major advancements in this sector.
The market for methicillin-resistant Staphylococcus aureus (MRSA) therapy is expected to fall by just 01 Basis Point Share (BPS) in H1-2022, according to FMI. The disruption created by the COVID-19 pandemic, as well as the lack of clear protocols for MRSA treatment in numerous countries, are key factors in the decline of BPS. Moreover, a decline of 10 BPS will be observed in the market within the periods of H1-2022 outlook over H1-2022 projected.
On the other hand, there are certain advantages for the industry, such as combination therapy with Vancomycin and Daptomycin. Physicians employ heterogeneous practice patterns with vancomycin or daptomycin monotherapy for MRSA, with combination antibiotic therapy reserved for patients at higher risk of treatment failure.
Sales of methicillin-resistant staphylococcus aureus (MRSA) treatment grew at a CAGR of 4.1% between 2015 and 2021.
The primary factors contributing to the development of the methicillin-resistant staphylococcus aureus (MRSA) treatment market are increase in the worldwide occurrence of MRSA infections, a rise in public and private funding for R&D of new anti-MRSA drugs and their enhanced screening.
For instance, as per the CDC, around 2% of the overall population carries MRSA. Moreover, the growing practice of prescribing inappropriate and unnecessary antibiotics leading to the increase in MRSA infections is expected to boost the growth of the global market.
In addition, companies are focusing on product releases and research for the detection of MRSA, which is boosting the global MRSA treatment market.
For instance, in February 2019, Paratek Pharmaceuticals, Inc. launched NUZYRA (omadacycline) in the U.S. market.
Considering this, FMI expects the global methicillin-resistant staphylococcus aureus (MRSA) treatment market to grow at a CAGR of 4.3% through 2030.
Principal Consultant
Poor access to MRSA treatment and misdiagnoses of MRSA infections are the primary factors limiting the growth of the MSRA treatment market.
S. aureus and MRSA produce considerable economic challenges for healthcare professionals owing to the effect they have on quality of care, patient safety, and overall healthcare expenses. High cost related with MRSA infections treatment is anticipated to hinder the treatment adoption rate specifically in emerging regions.
In addition, incorrect diagnoses of MRSA may result into inappropriate delivery and management of patient care, which, in turn, results into severe primary and secondary complications, including death. All such factors may hinder the market growth in the near future.
The U.S. is estimated to account for around 93.2% of the North America methicillin-resistant staphylococcus aureus (MRSA) treatment market in 2022.
U.S. is anticipated to lead the global MRSA treatment market over the forecast period. This market share is majorly owing to the funding by U.S. based companies in the research and development of assessment tools for MRSA infection. In addition, the increase in government support for treatment of MRSA lung infection in patients with cystic fibrosis has boosted the market.
For instance, Cystic Fibrosis Foundation, in 2018, at North American Cystic Fibrosis Conference declared that it will spend a minimum of USD 100 million for the next five years to support enhanced diagnosis, detection, prevention, and treatment of infections associated to cystic fibrosis.
U.K. is estimated to account for 14.7% of the Europe methicillin-resistant staphylococcus aureus (MRSA) treatment market in 2022.
U.K. is the one of the prominent country in the European market owing to research grants by the private & public companies in the European countries to boost the research and development of anti-MRSA antibiotics.
In addition, the government of the UK is undertaking serious steps to avoid the incidence of SSI (surgical site infections) in the nation. Thus, the increasing efforts and preventive measures undertaken by the government for surgical site infections control are leading to the growth of the market in U.K.
The methicillin-resistant staphylococcus aureus (MRSA) treatment market in China is estimated to be worth US$ 156.6 Mn in 2022 in the global market.
China is expected to observe considerable growth during the forecast period owing to a huge patient pool and growing number of expansion strategies by key players to grow their presence in the country.
For instance, in 2017, Basilea Pharmaceutica Ltd. entered into a licensed agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. for expansion of Basilea's antibiotic Zevtera, broad spectrum anti-bacterial, which can address MRSA in China, Hong Kong, and Macao
Demand for methicillin-resistant staphylococcus aureus (MRSA) treatment in India is expected to rise at around 5.4% CAGR over the forecast period.
India is expected to witness considerable growth owing to larger patient population and the uncontrolled utilization of antibiotics in India. Resistance to antibiotics is continuously growing due to incomplete prescribed course of antibiotics that allows some bacteria to persist, grow a resistance to the antibiotic.
Moreover, misuse of antibiotics in non-regulated and developing nations is also anticipated to drive the cases of MRSA infections in the coming years. This is leading to increasing demand for the MRSA infection treatment.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By drug class, glycopeptides is anticipated to hold the maximum share of 61.2% in 2022, expanding at rate of nearly 4.1% during the forecast period, due to growing focus of market players on manufacturing of advanced drugs in this class. Vancomycin and teicoplanin are some of the present glycopeptide drugs in the market.
Moreover, in 2017, Cardiome Pharma Corp. launched Xydalba in Sweden, Finland, and the Republic of Ireland. Xydalba is approved by the European Medicines Agency (EMA) for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults.
By indication, skin and soft tissue infections (SSTIs) will lead the market and is projected to account for 40.9% of the total market revenue share in 2022.
The growing incidence of MRSA (methicillin-resistant staphylococcus aureus) infections has led to the need for novel therapies to fight the serious skin and soft tissue infections. Moreover, new product launches will drive the growth of the skin and soft tissue infections (SSTIs) segment over the forecast period.
In terms of route of administration, intravenous segment in projected to account for 57.2% of the total market share in 2022.
The intravenous route of administration is the most preferred route as it is the first line of therapy and the fastest route of drug delivery. This delivers the drug rapidly and gives the patient rapid relieve from the disease. This enhances the drug action and gives the patient first line of treatment.
By types of MRSA, healthcare acquired MRSA will lead the market and is projected to account for 51.2% of the total market revenue share in 2022.
Hospital-acquired MRSA hospitalizations are those with a secondary or principal MRSA detection that is not present on admission; this indicates that the MRSA condition occurred during the hospitalization. The hospital acquired MSRA cases is increasing due to the rising number of surgical procedures and unhygienic conditions.
By distribution channel, hospital pharmacies segment is anticipated to hold the maximum share of 62.6% in 2022, expanding at rapid rate of 3.9% CAGR during the forecast period.
The number of hospitals are growing, particularly in the developed nations, which is anticipated to surge the demand for methicillin-resistant staphylococcus aureus (MRSA) treatment in hospitals. Moreover, presence of well-developed infrastructure and availability of advanced equipment supports the development of the segment.
Also, the increasing patient admission in hospitals is increasing the use of these drugs in hospitals, thus driving the sales in hospital pharmacies.
Companies operating in the Methicillin-Resistant Staphylococcus Aureus (MRSA) treatment market are moderately competitive by nature, with a presence of several players. These players are involved in a number of strategic alliances. The product launch and acquisition accelerates the manufacturer’s strategy to capitalize on the market share and capture the significant share of market. Some of the recent instances include:
| Attribute | Details |
|---|---|
| Forecast Period | 2015 to 2021 |
| Historical Data Available for | 2022 to 2030 |
| Market Analysis | USD Million for Value |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, BENELUX, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, South Africa |
| Key Segments Covered | Drug Class, Indication, Route of Administration, Types of MSRA, Distribution Channel and Region |
| Key Companies Profiled | Pfizer, Inc.; Allergan Plc.; Johnsons & Johnson; Colgate-Palmolive Company; The Procter & Gamble; Merck & Co., Inc.; Baxter Healthcare Corporation; Fresenius Kabi LLC; Sandoz Inc.; Teva Pharmaceutical Industries ltd.; Mylan N. V.; Dr.Reddy's Laboratories Inc.; Cumberland Pharmaceuticals Inc.; Durata Therapeutics Inc.; Melinta Therapeutics, Inc.; Debiopharm International S.A.; Cardinal Health; Amazon Inc.; Herbal Intervention, LLC; 3M ESPE Dental Products; Patterson Dental Supply Inc.; The Kroger Company; Crown Laboratories, Inc.; Atlantic Biologicals Corp.; Bio-Germ Protection LLC; Apollo Health and Beauty Care |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global methicillin-resistant staphylococcus aureus (MRSA) treatment market is worth US$ 3.8 Bn in 2021 and is set to expand 1.4X over the forecast years.
The sales of methicillin-resistant staphylococcus aureus (MRSA) treatment in the market have grown at a CAGR of nearly 4.1% between 2015 and 2021.
The methicillin-resistant staphylococcus aureus (MRSA) treatment market is expected to reach US$ 5.5 Bn by the end of 2030 with sales revenue expected to register CAGR of 4.3% over the forecast period.
North America currently holds the largest market share in the methicillin-resistant staphylococcus aureus (MRSA) treatment with an estimation of nearly 48.5% in 2022 of the global market share. U.S. continues to be the leading contributor with a market value over US$ 1.7 Bn in 2022.
Demand of methicillin-resistant staphylococcus aureus (MRSA) treatment market is expected to register growth in Europe at rate of 4.4% CAGR during the forecast period.
The methicillin-resistant staphylococcus aureus (MRSA) treatment in China is likely to observe growth with an impressive CAGR of 5.1% during the forecast period. The key factors fueling the development of the market include huge patient pool and growing number of expansion strategies by key players to grow their presence in the country.
Development of alternative oral & topical dosage forms, extension of antibiotic class to newer therapeutics, rise of specialized companies in antibiotics developments and commercialization and national healthcare authority’s active engagement to combat MRSA are key trends driving sales of methicillin-resistant staphylococcus aureus (MRSA) treatment market across the globe.
Japan’s methicillin-resistant staphylococcus aureus (MRSA) treatment market is offering lucrative growth opportunities and is expected to exhibit healthy growth of 5.6% CAGR during the forecast period. South Korea market expected to exhibit healthy growth of 7.0% CAGR during the forecast period.
U.S., Germany, France, U.K. and Italy are the top 5 countries driving the demand for methicillin-resistant staphylococcus aureus (MRSA) treatment market.
Leading companies of methicillin-resistant staphylococcus aureus (MRSA) treatment are Pfizer, Inc., Allergan Plc., Johnsons & Johnson, Colgate-Palmolive Company, The Procter & Gamble, Merck & Co., Inc., Baxter Healthcare Corporation, Fresenius Kabi LLC, Sandoz Inc., Teva Pharmaceutical Industries ltd., Mylan N. V., Dr.Reddy's Laboratories Inc., Cumberland Pharmaceuticals Inc., Durata Therapeutics Inc., Melinta Therapeutics, Inc., Debiopharm International S.A., Cardinal Health, Amazon Inc., Herb
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Market Background 4.1. COVID19 Crisis Analysis 4.1.1. Current COVID19 Statistics and Probable Future Impact 4.1.2. Current GDP Projection and Probable Impact 4.1.3. Current Economic Projection as compared to 2008 Economic analysis 4.1.4. COVID19 and Impact Analysis 4.1.4.1. Revenue By Drug Class 4.1.4.2. Revenue By Route of Administration 4.1.4.3. Revenue By Country 4.1.5. 2020 Market Scenario 4.1.6. Quarter by Quarter Forecast 4.1.7. Projected recovery Quarter 4.1.8. Recovery Scenario – Short term, Midterm and Long Term Impact 4.2. Macro-Economic Factors 4.2.1. Global GDP Growth Outlook 4.2.2. Global Healthcare Outlook 4.3. Forecast Factors - Relevance & Impact 4.3.1. Historical Growth of Top Players 4.3.2. New Product Approval and Launch 4.3.3. Adoption of MRSA Treatment 4.3.4. Cost of MRSA Treatment 4.3.5. Increasing Epidemic of MRSA Infections 4.4. Market Dynamics 4.4.1. Drivers 4.4.2. Restraints 4.4.3. Opportunities 5. Market Context 5.1. Product USPs/ Features 5.2. Epidemiological Forecast for MRSA (2014–2024) 5.2.1. Hospitalized Incident Cases of MRSA 5.2.2. Sex-Specific Hospitalized Incident Cases of MRSA 5.2.3. Age-Specific Hospitalized Incidence of MRSA 5.2.4. Age-Standardized Hospitalized Incidence Rate of MRSA 5.3. Pipeline Assessment 5.3.1. Pipeline Overview 5.3.2. Pipeline Breakdown by Region/Country 5.3.3. Pipeline Breakdown by Molecule Type and Target 5.3.4. Drug Review Designations 5.3.5. Products in Clinical Development 5.4. New Product Approvals 5.5. Clinical Trial Assessment 5.5.1. Clinical Trials Overview 5.5.2. Top Sponsors of Clinical Trials in MRSA 5.5.3. Trial Breakdown by Region 5.5.4. Therapy Area Perspective 5.5.5. Enrolment Analytics 5.6. Product Adoption / Route of Administration Analysis 5.7. Regulatory Scenario 6. Global MRSA Treatment Market Value (US$ Mn) Analysis 2015-2021 and Forecast, 2022-2030 6.1. Historical Market Value (US$ Mn) Analysis, 2015-2021 6.2. Current and Future Market Value (US$ Mn) Projections, 2022-2030 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Opportunity Analysis, 2022-2030 7. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, By Drug Class 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2015-2021 7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2022-2030 7.3.1. Glycopeptides 7.3.1.1. Vancomycin 7.3.2. Lipopeptides 7.3.2.1. Daptomycin 7.3.3. Oxazolidinones 7.3.3.1. Linezolid 7.3.4. Glycylcycline 7.3.4.1. Tigecycline 7.3.5. Streptogramins 7.3.5.1. Quinupristin 7.3.5.2. Dalfopristin 7.3.6. Lincomycin 7.3.6.1. Clindamycin 7.3.7. Tetracycline 7.3.7.1. Doxycycline 7.3.7.2. Minocycline 7.3.8. Lipoglycopeptides 7.3.8.1. Dalbavancin 7.3.8.12. Telavancin 7.3.8.3. Oritavancin 7.3.9. Antiseptics 7.3.9.1. Chlorhexidine 7.3.9.2. Cetylpyridinium Chloride 7.3.9.3. Hydrogen Peroxide 7.3.9.4. Phenols 7.3.10. Naturals/Herbals 7.3.11. Others 7.4. Market Attractiveness Analysis By Drug Class 8. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, By Indication 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2015-2021 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022-2030 8.3.1. Skin and Soft Tissue Infections (SSTIs) 8.3.2. Pneumonia 8.3.3. Bloodstream Infections 8.3.4. Surgical and Medical Infections 8.3.5. Others 8.4. Market Attractiveness Analysis By Indication 9. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, By Route of Administration 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2015-2021 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2030 9.3.1. Intravenous 9.3.2. Oral 9.3.3. Topical 9.3.4. Nasal 9.3.5. Cutaneous 9.3.6. Intramuscular 9.4. Market Attractiveness Analysis By Route of Administration 10. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, By Types of MRSA 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2015-2021 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Types of MRSA, 2022-2030 10.3.1. Healthcare Acquired MRSA 10.3.2. Community Acquired MRSA 10.3.3. Hospital Acquired MRSA 10.4. Market Attractiveness Analysis By Types of MRSA 11. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, By Distribution Channels 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channels, 2015-2021 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channels, 2022-2030 11.3.1. Hospital Pharmacies 11.3.2. Retail Pharmacies 11.3.3. Drug Stores 11.3.4. Online Pharmacies 11.4. Market Attractiveness Analysis By Distribution Channels 12. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, by Region 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2030 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia Pacific 12.3.6. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Drug Class 13.3.3. By Indication 13.3.4. By Route of Administration 13.3.5. By Types of MRSA 13.3.6. By Distribution Channels 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. Latin America MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Drug Class 14.3.3. By Indication 14.3.4. By Route of Administration 14.3.5. By Types of MRSA 14.3.6. By Distribution Channels 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. Europe MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Russia 15.3.1.8. Rest of Europe 15.3.2. By Drug Class 15.3.3. By Indication 15.3.4. By Route of Administration 15.3.5. By Types of MRSA 15.3.6. By Distribution Channels 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. South Asia and Oceania MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030 16.3.1. By Country 16.3.1.1. India 16.3.1.2. ASEAN 16.3.1.3. Australia 16.3.1.4. New Zealand 16.3.2. By Drug Class 16.3.3. By Indication 16.3.4. By Route of Administration 16.3.5. By Types of MRSA 16.3.6. By Distribution Channels 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. East Asia MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Drug Class 17.3.3. By Indication 17.3.4. By Route of Administration 17.3.5. By Types of MRSA 17.3.6. By Distribution Channels 17.4. Market Attractiveness Analysis 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. Oceania MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Drug Class 18.3.3. By Indication 18.3.4. By Route of Administration 18.3.5. By Types of MRSA 18.3.6. By Distribution Channels 18.4. Market Attractiveness Analysis 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 19. Middle East and Africa MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030 19.1. Introduction 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Turkey 19.3.1.3. South Africa 19.3.1.4. Rest of Middle East and Africa 19.3.2. By Drug Class 19.3.3. By Indication 19.3.4. By Route of Administration 19.3.5. By Types of MRSA 19.3.6. By Distribution Channels 19.4. Market Attractiveness Analysis 19.5. Key Market Participants - Intensity Mapping 19.6. Drivers and Restraints - Impact Analysis 20. Emerging Countries MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030 20.1. Introduction 20.1.1. Market Value Proportion Analysis, By Key Countries 20.1.2. Global Vs. Country Growth Comparison 20.2. China MRSA Treatment Market Analysis 20.2.1. By Drug Class 20.2.2. By Indication 20.2.3. By Route of Administration 20.2.4. By Types of MRSA 20.2.5. By Distribution Channels 20.3. India MRSA Treatment Market Analysis 20.3.1. By Drug Class 20.3.2. By Indication 20.3.3. By Route of Administration 20.3.4. By Types of MRSA 20.3.5. By Distribution Channels 20.4. Brazil MRSA Treatment Market Analysis 20.4.1. By Drug Class 20.4.2. By Indication 20.4.3. By Route of Administration 20.4.4. By Types of MRSA 20.4.5. By Distribution Channels 21. Key Countries MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030 21.1. U.S. MRSA Treatment Market Analysis 21.1.1. By Drug Class 21.1.2. By Indication 21.1.3. By Route of Administration 21.1.4. By Types of MRSA 21.1.5. By Distribution Channels 21.2. Canada MRSA Treatment Market Analysis 21.2.1. By Drug Class 21.2.2. By Indication 21.2.3. By Route of Administration 21.2.4. By Types of MRSA 21.2.5. By Distribution Channels 21.3. Mexico MRSA Treatment Market Analysis 21.3.1. By Drug Class 21.3.2. By Indication 21.3.3. By Route of Administration 21.3.4. By Types of MRSA 21.3.5. By Distribution Channels 21.4. U.K. MRSA Treatment Market Analysis 21.4.1. By Drug Class 21.4.2. By Indication 21.4.3. By Route of Administration 21.4.4. By Types of MRSA 21.4.5. By Distribution Channels 21.5. Germany MRSA Treatment Market Analysis 21.5.1. By Drug Class 21.5.2. By Indication 21.5.3. By Route of Administration 21.5.4. By Types of MRSA 21.5.5. By Distribution Channels 21.6. France MRSA Treatment Market Analysis 21.6.1. By Drug Class 21.6.2. By Indication 21.6.3. By Route of Administration 21.6.4. By Types of MRSA 21.6.5. By Distribution Channels 21.7. Italy MRSA Treatment Market Analysis 21.7.1. By Drug Class 21.7.2. By Indication 21.7.3. By Route of Administration 21.7.4. By Types of MRSA 21.7.5. By Distribution Channels 21.8. Spain MRSA Treatment Market Analysis 21.8.1. By Drug Class 21.8.2. By Indication 21.8.3. By Route of Administration 21.8.4. By Types of MRSA 21.8.5. By Distribution Channels 21.9. BENELUX MRSA Treatment Market Analysis 21.9.1. By Drug Class 21.9.2. By Indication 21.9.3. By Route of Administration 21.9.4. By Types of MRSA 21.9.5. By Distribution Channels 21.10. Russia MRSA Treatment Market Analysis 21.10.1. By Drug Class 21.10.2. By Indication 21.10.3. By Route of Administration 21.10.4. By Types of MRSA 21.10.5. By Distribution Channels 21.11. Japan MRSA Treatment Market Analysis 21.11.1. By Drug Class 21.11.2. By Indication 21.11.3. By Route of Administration 21.11.4. By Types of MRSA 21.11.5. By Distribution Channels 21.12. South Korea MRSA Treatment Market Analysis 21.12.1. By Drug Class 21.12.2. By Indication 21.12.3. By Route of Administration 21.12.4. By Types of MRSA 21.12.5. By Distribution Channels 21.13. ASEAN MRSA Treatment Market Analysis 21.13.1. By Drug Class 21.13.2. By Indication 21.13.3. By Route of Administration 21.13.4. By Types of MRSA 21.13.5. By Distribution Channels 21.14. Australia MRSA Treatment Market Analysis 21.14.1. By Drug Class 21.14.2. By Indication 21.14.3. By Route of Administration 21.14.4. By Types of MRSA 21.14.5. By Distribution Channels 21.15. New Zealand MRSA Treatment Market Analysis 21.15.1. By Drug Class 21.15.2. By Indication 21.15.3. By Route of Administration 21.15.4. By Types of MRSA 21.15.5. By Distribution Channels 21.16. GCC Countries MRSA Treatment Market Analysis 21.16.1. By Drug Class 21.16.2. By Indication 21.16.3. By Route of Administration 21.16.4. By Types of MRSA 21.16.5. By Distribution Channels 21.17. Turkey MRSA Treatment Market Analysis 21.17.1. By Drug Class 21.17.2. By Indication 21.17.3. By Route of Administration 21.17.4. By Types of MRSA 21.17.5. By Distribution Channels 21.18. South Africa MRSA Treatment Market Analysis 21.18.1. By Drug Class 21.18.2. By Indication 21.18.3. By Route of Administration 21.18.4. By Types of MRSA 21.18.5. By Distribution Channels 22. Market Structure Analysis 22.1. Market Analysis by Tier of Companies 22.2. Market Share Analysis of Top Players 22.3. Market Presence Analysis 22.3.1. Regional Footprint by Players 22.3.2. Product Foot print by Players 22.3.3. Channel Foot Print by Players 23. Competition Analysis 23.1. Competition Dashboard 23.2. Competition Benchmarking 23.3. Competition Deep Dive (Tentative List) 23.3.1. Pfizer, Inc. 23.3.1.1. Overview 23.3.1.2. Product Portfolio 23.3.1.3. Profitability by Market Segments (Product/Channel/Region) 23.3.1.4. Sales Footprint 23.3.1.5. Strategy Overview 23.3.1.5.1. Marketing Strategy 23.3.1.5.2. Product Strategy 23.3.1.5.3. Channel Strategy 23.3.2. Allergan Plc. 23.3.2.1. Overview 23.3.2.2. Product Portfolio 23.3.2.3. Profitability by Market Segments (Product/Channel/Region) 23.3.2.4. Sales Footprint 23.3.2.5. Strategy Overview 23.3.2.5.1. Marketing Strategy 23.3.2.5.2. Product Strategy 23.3.2.5.3. Channel Strategy 23.3.3. Johnsons & Johnson 23.3.3.1. Overview 23.3.3.2. Product Portfolio 23.3.3.3. Profitability by Market Segments (Product/Channel/Region) 23.3.3.4. Sales Footprint 23.3.3.5. Strategy Overview 23.3.3.5.1. Marketing Strategy 23.3.3.5.2. Product Strategy 23.3.3.5.3. Channel Strategy 23.3.4. Colgate-Palmolive Company 23.3.4.1. Overview 23.3.4.2. Product Portfolio 23.3.4.3. Profitability by Market Segments (Product/Channel/Region) 23.3.4.4. Sales Footprint 23.3.4.5. Strategy Overview 23.3.4.5.1. Marketing Strategy 23.3.4.5.2. Product Strategy 23.3.4.5.3. Channel Strategy 23.3.5. The Procter & Gamble 23.3.5.1. Overview 23.3.5.2. Product Portfolio 23.3.5.3. Profitability by Market Segments (Product/Channel/Region) 23.3.5.4. Sales Footprint 23.3.5.5. Strategy Overview 23.3.5.5.1. Marketing Strategy 23.3.5.5.2. Product Strategy 23.3.5.5.3. Channel Strategy 23.3.6. Merck & Co., Inc. 23.3.6.1. Overview 23.3.6.2. Product Portfolio 23.3.6.3. Profitability by Market Segments (Product/Channel/Region) 23.3.6.4. Sales Footprint 23.3.6.5. Strategy Overview 23.3.6.5.1. Marketing Strategy 23.3.6.5.2. Product Strategy 23.3.6.5.3. Channel Strategy 23.3.7. Baxter Healthcare Corporation 23.3.7.1. Overview 23.3.7.2. Product Portfolio 23.3.7.3. Profitability by Market Segments (Product/Channel/Region) 23.3.7.4. Sales Footprint 23.3.7.5. Strategy Overview 23.3.7.5.1. Marketing Strategy 23.3.7.5.2. Product Strategy 23.3.7.5.3. Channel Strategy 23.3.8. Fresenius Kabi LLC 23.3.8.1. Overview 23.3.8.2. Product Portfolio 23.3.8.3. Profitability by Market Segments (Product/Channel/Region) 23.3.8.4. Sales Footprint 23.3.8.5. Strategy Overview 23.3.8.5.1. Marketing Strategy 23.3.8.5.2. Product Strategy 23.3.8.5.3. Channel Strategy 23.3.9. Sandoz Inc. 23.3.9.1. Overview 23.3.9.2. Product Portfolio 23.3.9.3. Profitability by Market Segments (Product/Channel/Region) 23.3.9.4. Sales Footprint 23.3.9.5. Strategy Overview 23.3.9.5.1. Marketing Strategy 23.3.9.5.2. Product Strategy 23.3.9.5.3. Channel Strategy 23.3.10. Teva Pharmaceutical Industries ltd. 23.3.10.1. Overview 23.3.10.2. Product Portfolio 23.3.10.3. Profitability by Market Segments (Product/Channel/Region) 23.3.10.4. Sales Footprint 23.3.10.5. Strategy Overview 23.3.10.5.1. Marketing Strategy 23.3.10.5.2. Product Strategy 23.3.10.5.3. Channel Strategy 23.3.11. Mylan N. V. 23.3.11.1. Overview 23.3.11.2. Product Portfolio 23.3.11.3. Profitability by Market Segments (Product/Channel/Region) 23.3.11.4. Sales Footprint 23.3.11.5. Strategy Overview 23.3.11.5.1. Marketing Strategy 23.3.11.5.2. Product Strategy 23.3.11.5.3. Channel Strategy 23.3.12. Dr.Reddy's Laboratories Inc., 23.3.12.1. Overview 23.3.12.2. Product Portfolio 23.3.12.3. Profitability by Market Segments (Product/Channel/Region) 23.3.12.4. Sales Footprint 23.3.12.5. Strategy Overview 23.3.12.5.1. Marketing Strategy 23.3.12.5.2. Product Strategy 23.3.12.5.3. Channel Strategy 23.3.13. Cumberland Pharmaceuticals Inc. 23.3.13.1. Overview 23.3.13.2. Product Portfolio 23.3.13.3. Profitability by Market Segments (Product/Channel/Region) 23.3.13.4. Sales Footprint 23.3.13.5. Strategy Overview 23.3.13.5.1. Marketing Strategy 23.3.13.5.2. Product Strategy 23.3.13.5.3. Channel Strategy 23.3.14. Durata Therapeutics Inc. 23.3.14.1. Overview 23.3.14.2. Product Portfolio 23.3.14.3. Profitability by Market Segments (Product/Channel/Region) 23.3.14.4. Sales Footprint 23.3.14.5. Strategy Overview 23.3.14.5.1. Marketing Strategy 23.3.14.5.2. Product Strategy 23.3.14.5.3. Channel Strategy 23.3.15. Melinta Therapeutics, Inc. 23.3.15.1. Overview 23.3.15.2. Product Portfolio 23.3.15.3. Profitability by Market Segments (Product/Channel/Region) 23.3.15.4. Sales Footprint 23.3.15.5. Strategy Overview 23.3.15.5.1. Marketing Strategy 23.3.15.5.2. Product Strategy 23.3.15.5.3. Channel Strategy 23.3.16. Debiopharm International S.A. 23.3.16.1. Overview 23.3.16.2. Product Portfolio 23.3.16.3. Profitability by Market Segments (Product/Channel/Region) 23.3.16.4. Sales Footprint 23.3.16.5. Strategy Overview 23.3.16.5.1. Marketing Strategy 23.3.16.5.2. Product Strategy 23.3.16.5.3. Channel Strategy 23.3.17. Cardinal Health 23.3.17.1. Overview 23.3.17.2. Product Portfolio 23.3.17.3. Profitability by Market Segments (Product/Channel/Region) 23.3.17.4. Sales Footprint 23.3.17.5. Strategy Overview 23.3.17.5.1. Marketing Strategy 23.3.17.5.2. Product Strategy 23.3.17.5.3. Channel Strategy 23.3.18. Amazon Inc. 23.3.18.1. Overview 23.3.18.2. Product Portfolio 23.3.18.3. Profitability by Market Segments (Product/Channel/Region) 23.3.18.4. Sales Footprint 23.3.18.5. Strategy Overview 23.3.18.5.1. Marketing Strategy 23.3.18.5.2. Product Strategy 23.3.18.5.3. Channel Strategy 23.3.19. Herbal Intervention, LLC 23.3.19.1. Overview 23.3.19.2. Product Portfolio 23.3.19.3. Profitability by Market Segments (Product/Channel/Region) 23.3.19.4. Sales Footprint 23.3.19.5. Strategy Overview 23.3.19.5.1. Marketing Strategy 23.3.19.5.2. Product Strategy 23.3.19.5.3. Channel Strategy 23.3.20. 3M ESPE Dental Products 23.3.20.1. Overview 23.3.20.2. Product Portfolio 23.3.20.3. Profitability by Market Segments (Product/Channel/Region) 23.3.20.4. Sales Footprint 23.3.20.5. Strategy Overview 23.3.20.5.1. Marketing Strategy 23.3.20.5.2. Product Strategy 23.3.20.5.3. Channel Strategy 23.3.21. Patterson Dental Supply Inc. 23.3.21.1. Overview 23.3.21.2. Product Portfolio 23.3.21.3. Profitability by Market Segments (Product/Channel/Region) 23.3.21.4. Sales Footprint 23.3.21.5. Strategy Overview 23.3.21.5.1. Marketing Strategy 23.3.21.5.2. Product Strategy 23.3.21.5.3. Channel Strategy 23.3.22. The Kroger Company 23.3.22.1. Overview 23.3.22.2. Product Portfolio 23.3.22.3. Profitability by Market Segments (Product/Channel/Region) 23.3.22.4. Sales Footprint 23.3.22.5. Strategy Overview 23.3.22.5.1. Marketing Strategy 23.3.22.5.2. Product Strategy 23.3.22.5.3. Channel Strategy 23.3.23. Crown Laboratories, Inc. 23.3.23.1. Overview 23.3.23.2. Product Portfolio 23.3.23.3. Profitability by Market Segments (Product/Channel/Region) 23.3.23.4. Sales Footprint 23.3.23.5. Strategy Overview 23.3.23.5.1. Marketing Strategy 23.3.23.5.2. Product Strategy 23.3.23.5.3. Channel Strategy 23.3.24. Atlantic Biologicals Corp. 23.3.24.1. Overview 23.3.24.2. Product Portfolio 23.3.24.3. Profitability by Market Segments (Product/Channel/Region) 23.3.24.4. Sales Footprint 23.3.24.5. Strategy Overview 23.3.24.5.1. Marketing Strategy 23.3.24.5.2. Product Strategy 23.3.24.5.3. Channel Strategy 23.3.25. Bio-Germ Protection LLC 23.3.25.1. Overview 23.3.25.2. Product Portfolio 23.3.25.3. Profitability by Market Segments (Product/Channel/Region) 23.3.25.4. Sales Footprint 23.3.25.5. Strategy Overview 23.3.25.5.1. Marketing Strategy 23.3.25.5.2. Product Strategy 23.3.25.5.3. Channel Strategy 23.3.26. Apollo Health and Beauty Care 23.3.26.1. Overview 23.3.26.2. Product Portfolio 23.3.26.3. Profitability by Market Segments (Product/Channel/Region) 23.3.26.4. Sales Footprint 23.3.26.5. Strategy Overview 23.3.26.5.1. Marketing Strategy 23.3.26.5.2. Product Strategy 23.3.26.5.3. Channel Strategy 24. Assumptions and Acronyms Used 25. Research Methodology
Explore Healthcare Insights
View Reports
Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market
